Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.76 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | VEGFA | P15692 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4390048 | 0.86 | MAPK14 (1.00) | MAPK14HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4467116 | 0.83 | MAPK14 (0.70) | MAPK14HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10048362 | 0.82 | MAPK14 (0.69) | MAPK14HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4473416 | 0.81 | MAPK14 (1.00) | MAPK14HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4476593 | 0.80 | MAPK14 (1.00) | MAPK14HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4470415 | 0.80 | MAPK14 (1.00) | MAPK14HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3049936 | 0.80 | MAPK14 (1.00) | MAPK14HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL271730 | 0.78 | MAPK14 (0.68) | MAPK14HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4477324 | 0.78 | MAPK14 (0.78) | MAPK14HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3520732 | 0.77 | DAPK1 (0.50) | MAPK14HTTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070088033-A1 | Diaryl Substituted Pyridinones | DEVADAS BALEKUDRU | 2007-04-19 | — | — | US | claimed |
| US-20060211694-A1 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT (US) | 2006-09-21 | — | — | US | claimed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | claimed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | DEVADAS BALEKUDRU | 2007-04-19 | — | — | US | disclosed |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | DEVADAS BALEKUDRU | 2007-04-19 | — | — | US | disclosed |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | DEVADAS BALEKUDRU | 2007-04-19 | — | — | US | disclosed |
| US-20060211694-A1 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT (US) | 2006-09-21 | — | — | US | disclosed |
| US-7067540-B2 | Substituted pyridinones | PHARMACIA CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | MAPK14 41/4885HTT 4654/4885MEN1 4261/4885 |
| US-20060211694-A1 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | LTB4R2, LTB4R, MAPK1 | MAPK14 79/4885HTT 4853/4885MEN1 4779/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | MAPK14 53/4885HTT 4506/4885MEN1 3919/4885 |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | MAPK1, MAPK6, MAP3K6 | MAPK14 46/4885HTT 4570/4885MEN1 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.